FBB Biomed is a pioneering startup operating in the medical diagnostics sector, specifically focusing on brain diseases. The company has developed a groundbreaking alternative to the traditional, often painful and inaccurate, method of diagnosing brain diseases through spinal taps. Instead, FBB Biomed offers a blood test that leverages proprietary RNA signatures and machine learning algorithms to differentiate between specific brain diseases such as Multiple Sclerosis, Parkinson’s Disease, and Alzheimer’s Disease.

The company's innovative approach addresses a significant market need, given that approximately 600,000 people are diagnosed with a brain disease each year in the US alone, and up to 30% of these diagnoses are inaccurate. FBB Biomed's blood test aims to bring precision to this field, offering a minimally invasive and highly accurate method for differential diagnosis.

FBB Biomed's business model revolves around the sale of its reagent, a substance used for chemical analysis, which enables novel next-generation sequencing (NGS) diagnostics. This reagent allows neurologists to perform a 'liquid biopsy' for brain diseases using standard laboratory sequencing equipment and protocols, without the need for new hardware or processes.

The company has recently filed a provisional patent with the US Patent and Trademark Office, demonstrating its commitment to protecting its unique technology and securing its market position.

Keywords: Medical Diagnostics, Brain Diseases, Blood Test, RNA Signatures, Machine Learning, Differential Diagnosis, Next-Generation Sequencing, Liquid Biopsy, Reagent, Provisional Patent.